- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.08. | Amgen drops early-stage obesity drug, upping pressure on MariTide | ||
| 04.08. | Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart | ||
| 04.08. | Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout | ||
| 04.08. | Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex's Journavx | ||
| 04.08. | Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact | ||
| 04.08. | Merck's $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials | ||
| 03.08. | BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger | ||
| 31.07. | Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail | ||
| 31.07. | Apnimed's IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch | ||
| 30.07. | BMS CEO Boerner doesn't 'feel any compulsion to make deals' despite lack of M&A this year | ||
| 30.07. | Attovia, Braveheart Bio and Vogenx seek more than $500M across trio of IPOs | ||
| 30.07. | Takeda scraps another phase 2 celiac disease therapy, narrowing pipeline to one | ||
| 30.07. | J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout | ||
| 30.07. | Sanofi's new CEO 'looking deeply' at late-stage pipeline as clinical clearout continues | ||
| 29.07. | Merck posts-then pulls-trial plan for PD-1xVEGF and TROP2 ADC combination | ||
| 29.07. | 'We have what we need to grow:' Biogen CEO happy to ease off the M&A for a while | ||
| 29.07. | Novo Nordisk fails to dismiss lawsuit over CagriSema readout | ||
| 29.07. | Processa acquires Vidya for potential BTK inhibitor rival to Novartis' Rhapsido | ||
| 29.07. | 'Reverse mergers are increasingly popular': Caldera hops on Synlogic's Nasdaq listing | ||
| 29.07. | Vertex's latest autoimmune TCE play involves $28M upfront to AbCellera | ||
| 28.07. | Eli Lilly tops new biopharma ranking on launch success, development speed | ||
| 28.07. | Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options | ||
| 28.07. | Altimmune's next-gen GLP-1 curbs heavy drinking in 'unequivocal' ph. 2 alcohol use disorder win | ||
| 28.07. | GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AstraZeneca's backyard | ||
| 28.07. | Atea's hepatitis C asset matches Gilead's Epclusa in phase 3 trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.